

SUVEN Life Sciences Ltd



News Release

PAT up by 51%; R&D spend at 33% of Revenue.

HYDERABAD, INDIA (Jul' 31, 2007) – SUVEN LIFE Science's Board of Directors meeting held today in Hyderabad announced the results that the PAT went up by 51% from Rs. 208 lacs to Rs. 315 lacs while the revenue increased by 13% to Rs. 2898 lacs for the quarter ending Jun' 2007 compared to Rs.2561 lacs for the previous quarter of same period. Export sales constitute 64% of total sales recorded during the quarter.

Suven's major thrust on **innovative R&D in Drug Discovery** continues with a total expenditure (revenue & capital) of **Rs. 944 lacs** recording about **33% of revenue** for the quarter.

The Board of Directors has recommended a dividend of 25% per annum on a face value of Rs.1 share for the financial year 2006-07.

The Board has also in its meeting held on 31st July 2007 considered and approved to raise funds to the tune of \$ 50 Million or its equivalent of any other Foreign / Indian currencies either by way of international offerings and / or domestic offerings for purpose of meeting its R&D expenditure for conducting Clinical Trials up to proof of concept (Phase 2) of our New Chemical Entity (NCE) SUVN – 502 for Alzheimer's disease and for creation of dedicated Drug Discovery Centre, subject to necessary consents / approvals.

Suven Life Sciences is a Hyderabad based Life Sciences Company a **Collaborative Research Partner (CRP) in Drug Discovery** for global pharma major is a pioneer in **Contract Research and Manufacturing Services (CRAMS)** since 1995 and **Drug Discovery Development Support Services (DDDSS)** since 2005. Suven has been involved in development of path breaking technologies for global pharma companies for more than a decade. Suven was awarded "**Partner of Choice in Drug Discovery for CNS**" by Frost & Sullivan in 2005.

A focused provider of DDDSS for development of New Chemical Entities to life sciences companies, Suven's commitment to protection of intellectual property, maximization of return on R&D investments for collaborative research partners, ability to offer full spectrum of services from discovery to market launch and provide technologies and expertise in different therapeutic areas. Suven has R&D strength of more than 190 professionals with the state of the art infrastructure for Drug Discovery and development activities with 30 clinical research professionals and the front end project management services from New Jersey, USA. For more information on Suven, please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;